Blue Jet Healthcare share price today

Blue Jet Healthcare Ltd's share price was ₹553.80 at the close on 6 November 2026. It has been rising for 15 weeks. That is 3.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹344 and ₹626, and at that close it sat 74% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Blue Jet Healthcare Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row.

Over the last 3 years the share price moved +42% while the NIFTY 500 moved +27%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: revenue down on a year earlier for 4 quarters in a row and profit down on a year earlier for 4 quarters in a row.

1. Revenue down on a year earlier for 4 quarters in a row

   In the June 2026 quarter revenue was ₹293 crore, -17.5% on a year earlier.

   Why: Revenue fell because some contrast media sales were not counted yet. Customer contracts count sales on delivery, and container shortages and longer transit kept goods in transit.

   Next results: check whether the higher goods in transit are counted as sales next quarter.

   From the earnings call on 3 Aug 2026.

2. Profit down on a year earlier for 4 quarters in a row

   In the June 2026 quarter profit was ₹78 crore, -14.3% on a year earlier.

   Why: Profit fell because raw material costs rose and the mix of products sold was less favorable.

   Next results: check whether customer contracts reset prices as raw material prices settle.

   From the earnings call on 3 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Blue Jet Healthcare reported revenue of ₹293 crore, down 17.5% from ₹355 crore a year earlier, and a profit of ₹78.0 crore, down 14.3% from ₹91.0 crore.

Blue Jet Healthcare results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Blue Jet Healthcare's management discussed these results on a call held on 3 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Blue Jet Healthcare closed at ₹553.80 on 6 November 2026, down 7.4% from ₹598.15 a year earlier (7 November 2025) and up 42.1% over three years. Its highest weekly close since November 2023 was ₹1,010.20 on 18 July 2025.

Blue Jet Healthcare share price: then and now

Weekly closing prices. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

162 weekly closes from 3 November 2023 to 6 November 2026.

6 Nov 2026: Blue Jet Healthcare closed at ₹553.80, up 9.8% on the week and up 7.6% on the month. 11 Sep 2026: ex-date for a dividend of ₹1.20 a share, record date 14 Sep 2026.

Earlier

• 3 Aug 2026: Blue Jet Healthcare held its results call for April to June 2026. Management guided: PI/API: strong order book and very good visibility for at least the next 3 or 4 quarters.
• Results for April to June 2026: Revenue down 17.5% and profit down 14.3% on a year earlier.

Blue Jet Healthcare paid ₹1.20 a share in regular dividends in the 12 months to 7 November 2026 (1 payment), a yield of 0.22% at the ₹553.80 close on 6 November 2026. The last was a dividend of ₹1.20 a share, ex-date 11 September 2026.

Blue Jet Healthcare dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Blue Jet Healthcare Ltd paid out 8% of its profit as dividends in FY26, and it paid a dividend in 3 of its last 7 reported years.

From the NSE corporate-actions record, read 7 November 2026.

On the call for April to June 2026, held on 3 August 2026, Blue Jet Healthcare's management guided: PI/API: strong order book and very good visibility for at least the next 3 or 4 quarters.

“We will not participate in the patented generic peptide opportunity, where there is congestion and significant price erosion.”V.K. Singh, Chief Operating Officer, on the call for April to June 2026

What management guided

• Contrast media: about ₹30 crore of higher goods in transit expected to be recognized next quarter; iodinated commercial batches planned by end-Q2 or beginning-Q3.
• Unit 3 backward integration: commissioning later this calendar year, commercial contribution in H2 FY27, and asset-block addition above ₹200 crore at commercialization.
• Vizag Phase 1: approximately ₹1,000 crore over 3 years; commercialization from end-FY29 to FY30, with ramp-up potentially in FY31 or FY32.
• FY27 capital spending: approximately ₹250 crore was cited, while Q&A said a similar amount to the analyst's cited ₹400 crore plan; exact figure unresolved.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 3 August 2026.

When Blue Jet Healthcare reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: PI/API order-book execution - check whether supply continuity converts into sustained reported growth.

Blue Jet Healthcare is on one of our India lists: Pharma stocks.

Blue Jet Healthcare Ltd earned ₹78.0 Cr of net profit in the Jun 2026 quarter, −14.3% on the same quarter a year earlier. Full-year FY26 profit was ₹248 Cr. Over 6 years profit has grown 9.4% a year on average. That is 26.6% of the quarter's revenue. The same quarter a year earlier earned ₹91.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹248 Cr (−18.7% on the year before).

Why profit moved: revenue changed −17.5% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed −31.5% and revenue −27.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

Blue Jet Healthcare Ltd reported ₹293 Cr of revenue in the Jun 2026 quarter, −17.5% on the same quarter a year earlier. Over 6 years it has grown 9.9% a year on average. The last full year, FY26, came in at ₹947 Cr. The last four reported quarters add to ₹885 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹947 Cr, −8.1% on the year before.

Recent pace: the last four quarters grew −27.2% on average, against 9.9% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −27.5%, against +12.8% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −34.6%, against +21.7% a year (rolling over).

Blue Jet Healthcare Ltd's operating margin was 33.0% in the Jun 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 7 years it has been between 30.0% and 41.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −0.6 percentage points on the year while gross margin changed +4.8 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 87% of Blue Jet Healthcare Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹334 Cr of operating cash against ₹248 Cr of profit. After ₹252 Cr of spending on assets, ₹82.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 87% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: the bigger use of cash is spending on new assets, at 7.2× depreciation over three years. The next section checks what that spending is building.

Blue Jet Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 240 days in FY26, up from 231 days in FY21. It spent ₹506 Cr on assets over the last 3 years. Customers take 131 days to pay, and stock sits for 157 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹947 Cr, each day of that cycle ties up about ₹2.6 Cr, so roughly ₹623 Cr is tied up in the business at any time.

FY26: customers took 131 days to pay and stock sat for 157 days, about 5.2 months of sales sitting as stock, for a full cycle of 240 days, longer than FY21's 231.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 157 days. Customers pay about 131 days after that. Suppliers are paid at 48 days. Together that makes the 240-day cycle.

Spending on assets: ₹506 Cr over the last 3 years, against ₹70.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹301 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Blue Jet Healthcare Ltd's P/E is 44.5×, in the middle of its own history: higher than 61% of past readings. Its usual P/E (the middle reading) is 41.1×, over 3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹13.55.

Why the multiple is where it is: over the past year earnings per share moved −18.8% while the price moved −7.4%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 3 years the price moved +12.4% a year; about +10.6% a year came from earnings growth and about +1.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Blue Jet Healthcare Ltd's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −27.5% in the latest quarter, against +75.7% at its best in 12 quarters, with ROCE falling at 25.1%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Blue Jet Healthcare Ltd earned a ROCE of 26% in FY26. Its return on capital used (ROIC) is 7.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 26.2% net margin and 0.58× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 26.2% net margin × 0.58× asset turnover × 1.21× leverage (assets divided by equity) ≈ 18.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 19.9% − 12.0% = +7.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

The 19.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 21.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Blue Jet Healthcare Ltd has total debt of ₹39.0 Cr against shareholder equity of ₹2,299 Cr as of Sep 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.00 in FY23 to 0.03 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Promoters cut their stake in Blue Jet Healthcare Ltd by 12.8 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 73.2% of the company. Domestic institutions moved +5.5 points over the same period, to 7.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: −12.8 points over 8 quarters, to 73.2%; Domestic institutions: +5.5 points over 8 quarters, to 7.5%; Foreign institutions: −0.3 points over 8 quarters, to 0.8%.

Why the owners changed: promoters drove it (−12.8 points), with the other side taken by domestic institutions (+5.5 points). They reduced their stake.

For Blue Jet Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

51.1 out of 100, rank 13 of 24 in Pharma - API & CRAMS, with 85% of the evidence available.

Blue Jet Healthcare Ltd scores 51.1 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 13. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.

The four parts add up to the total exactly: 7.7 + 19 + 14.4 + 10 = 51.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Blue Jet Healthcare ranks 13 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 51.1 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - API & CRAMS, all 24 compared on one page.

Blue Jet Healthcare is the 16th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Syngene International, Jubilant Pharmova and Concord Biotech. Just below it: Supriya Lifescience, Morepen Laboratories and IOL Chemicals & Pharmaceuticals.

Pharma - API & CRAMS companies close in size

13. Syngene International Ltd ₹16,256 crore
14. Jubilant Pharmova Ltd ₹14,716 crore
15. Concord Biotech Ltd ₹13,031 crore
16. Blue Jet Healthcare Ltd ₹9,550 crore
17. Supriya Lifescience Ltd ₹6,819 crore
18. Morepen Laboratories Ltd ₹6,211 crore
19. IOL Chemicals & Pharmaceuticals Ltd ₹5,557 crore

All 24 Pharma - API & CRAMS companies, largest first

Companies close in size in other industries

595. Can Fin Homes Ltd ₹9,582 crore · Finance - Housing
596. Aptus Value Housing Finance India Ltd ₹9,580 crore · Finance - Housing
597. Blue Jet Healthcare Ltd ₹9,550 crore
598. Inox Wind Ltd ₹9,540 crore · Capital Goods - Engineering Heavy
599. Park Medi World Ltd ₹9,490 crore · Hospitals/Medical Services

Sector Alpha, written by code from the published numbers. Data as of 6 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.